OncoMatch/Clinical Trials/NCT05668962
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Is NCT05668962 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Selpercatinib and Sodium Iodine I-131 for thyroid cancer.
Treatment: Selpercatinib · Sodium Iodine I-131 · rhTSH — This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Biomarker criteria
Required: RET fusion
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: ret-specific kinase inhibitor (selpercatinib, pralsetinib)
Lab requirements
Blood counts
leukocytes ≥3,000/mcL; ANC ≥1,500/mcL; platelets ≥100,000/mcL; hemoglobin ≥9 g/dL
Kidney function
creatinine ≤ institutional ULN OR creatinine clearance ≥30 mL/min
Liver function
total bilirubin ≤ 1.5 × institutional ULN OR <3.0 x institutional ULN for participants with Gilbert syndrome; AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN if the liver has tumor involvement
Cardiac function
NYHA class 2B or better; no history of Torsades de pointes, no myocardial infarction within 6 months, QTcF ≤470 msec on more than one ECG during Screening
Participants must have adequate organ and marrow function as defined below... Participants with known history or current symptoms of cardiac disease or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MedStar Washington Hospital Center · Washington D.C., District of Columbia
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify